The Utilization of Extracellular Proteins as Nutrients Is Suppressed by mTORC1  by Palm, Wilhelm et al.
Article
The Utilization of Extracellular Proteins as Nutrients
Is Suppressed by mTORC1Graphical AbstractHighlightsd Ras-directed protein macropinocytosis is an essential amino
acid source
d Lysosomal degradation of extracellular proteins activates
the mTORC1 pathway
d mTORC1 suppresses lysosomal catabolism of proteins
taken up from the environment
d mTORC1 inhibition promotes growth of amino-acid-starved
cells and hypovascular tumorsPalm et al., 2015, Cell 162, 259–270
July 16, 2015 ª2015 Elsevier Inc.
http://dx.doi.org/10.1016/j.cell.2015.06.017Authors
Wilhelm Palm, Youngkyu Park, Kevin
Wright, Natalya N. Pavlova, David A.




Unlike its growth-promoting activity
under amino-acid-replete conditions,
mTORC1 activation suppresses
proliferation when cells rely on
extracellular proteins as an amino acid
source. Importantly, inhibiting mTORC1
increases cell proliferation during amino
acid starvation within vascularly
compromised tumor regions, which may
have implications for the use of mTOR
inhibitors as therapeutics for cancer.
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Despite being surrounded by diverse nutrients,
mammalian cells preferentially metabolize glucose
and free amino acids. Recently, Ras-induced macro-
pinocytosis of extracellular proteins was shown to
reduce a transformed cell’s dependence on extracel-
lular glutamine. Here, we demonstrate that protein
macropinocytosis can also serve as an essential
amino acid source. Lysosomal degradation of extra-
cellular proteins can sustain cell survival and induce
activation of mTORC1 but fails to elicit significant cell
accumulation. Unlike its growth-promoting activity
under amino-acid-replete conditions, we discovered
that mTORC1 activation suppresses proliferation
when cells rely on extracellular proteins as an amino
acid source. Inhibiting mTORC1 results in increased
catabolism of endocytosed proteins and enhances
cell proliferation during nutrient-depleted conditions
in vitro and within vascularly compromised tumors
in vivo. Thus, by preventing nutritional consumption
of extracellular proteins, mTORC1 couples growth
to availability of free amino acids. These results
may have important implications for the use of
mTOR inhibitors as therapeutics.INTRODUCTION
To grow and divide, cells require a continuous supply of nutrients
that support energy production and macromolecular synthesis
(Cairns et al., 2011). Despite being surrounded by diverse bioen-
ergetic substrates, mammalian cells preferentially metabolize
low-molecular-weight nutrients such as glucose and amino
acids. However, proteins are the most abundant organic constit-
uents of body fluids, their combined amino acid content
exceeding the amount of monomeric amino acids in human
plasma by several orders of magnitude. Thus, extracellular pro-
teins have the potential to function as important alternative nutri-
ents, if accessible to cells.
The cells of metazoan organisms are instructed by external
cues to engage in nutrient uptake. Growth factor signaling
pathways not only stimulate cell-cycle progression, but also pro-
mote nutrient uptake and initiate anabolic metabolism, therebyensuring sufficient availability of building blocks for the synthesis
of macromolecules to increase cellular mass (Thompson, 2011).
Several growth-factor-directed signaling pathways enhance
cellular uptake of low-molecular-weight nutrients by increasing
expression or surface presentation of metabolite transporters.
For instance, both the PI3-kinase/Akt and Ras signaling path-
ways enhance glucose uptake (Manning and Cantley, 2007;
Pylayeva-Gupta et al., 2011; Yun et al., 2009). Ras GTPases
can also trigger internalization of extracellular macromolecules
through macropinocytosis, an evolutionarily conserved, non-
selective form of endocytosis (Bar-Sagi and Feramisco, 1986;
Mercer and Helenius, 2009). Macropinocytosis allows unicellular
amoeboid eukaryotes to live on extracellular macromolecules,
but whether it functions in nutrient acquisition of metazoan cells
is not well understood (Amyere et al., 2002). It was recently
shown that by promoting macropinocytosis, oncogenic K-Ras
signaling could reduce the dependence of proliferating cancer
cells on exogenous glutamine supply (Commisso et al., 2013).
This suggested that catabolism of extracellular proteins could
provide anaplerotic substrates that allow mammalian cells to
sustain mitochondrial bioenergetics and suppress apoptosis.
While growth factors regulate nutrient uptake, intracellular
nutrient levels can inform the cellular signaling state. The kinase
mammalian target of rapamycin complex 1 (mTORC1) is a cen-
tral regulator that coordinates cellular nutrient levels with inputs
from growth factor signaling to stimulate anabolic metabolism
and growth (Ma and Blenis, 2009; Shimobayashi and Hall,
2014). mTORC1 activity strictly depends on sufficient levels of
intracellular amino acids, which induce recruitment of mTORC1
to lysosomal membranes (Sancak et al., 2010). There, mTORC1
can be activated by further inputs from growth factor signaling.
Activated mTORC1 phosphorylates multiple targets that
concertedly enhance the generation of biomass. For instance,
through phosphorylation of S6 kinase (S6K) and 4E binding pro-
tein (4E-BP), mTORC1 increases 50 cap-dependent protein
translation (Ma and Blenis, 2009). Conversely, through inhibition
of Unc51-like kinase 1/2 (Ulk1/2), mTORC1 suppresses auto-
phagy, thereby preventing degradation of cellular matter (He
and Klionsky, 2009; Mizushima, 2010). By these means,
mTORC1 promotes cell growth in response to an environment
that provides favorable growth signals as well as ample nutrient
supply.
Here, we show that mTORC1 suppresses the ability of
mammalian cells to utilize extracellular proteins as a source of
amino acids to support proliferation. Even in Ras mutant
cells with constitutively activated macropinocytosis, mTORC1Cell 162, 259–270, July 16, 2015 ª2015 Elsevier Inc. 259
Figure 1. Physiological Levels of Extracel-
lular Proteins Provide Nutritional Benefits
for Wild-Type and K-Ras Mutant Cells
(A) Cell numbers of wild-type and heterozy-
gous K-RasG12D MEFs at day 3 of culture in
medium ±3% albumin lacking different nutrients
as indicated (glucose, non-essential amino acids
[NEAA], glutamine, essential amino acids [EAA],
leucine). The dashed line indicates starting cell
numbers. # below detection limit. *p < 0.05, **p <
0.01, ***p < 0.001.
(B) Growth curve of wild-type and K-RasG12D
MEFs in leucine-free medium ±3% albumin.
(C) Growth curve of wild-type MEFs expressing
myristoylated Akt1 (myr-Akt1) in leucine-free
medium ±3% albumin.
Data are represented as mean ± SD (n = 3). See
also Figure S1.impedes degradation of proteins internalized from the environ-
ment. Inhibition of mTORC1 elevates lysosomal catabolism of
extracellular proteins and promotes proliferation of cells both
during deprivation of amino acids in vitro and within poorly vas-
cularized tumor regions in vivo. By preventing nutritional utiliza-
tion of extracellular proteins, mTORC1 activity thus couples cell
growth to the supply of free amino acids.
RESULTS
Ras-Directed Macropinocytosis of Extracellular
Proteins Can Sustain Cell Viability and Proliferation
during Essential Amino Acid Starvation
We first asked whether the amino acids or hexose sugars con-
tained in proteins could support cellular metabolism by deter-
mining whether physiological levels of extracellular proteins
rescued viability and/or proliferation of cells cultured in the
absence of glucose or different classes of amino acids. To inves-
tigate whether activation of K-Ras signaling altered a cell’s ability
to metabolize extracellular proteins, we compared immortalized
mouse embryonic fibroblasts (MEFs) harboring wild-type K-Ras
or a constitutively active K-RasG12D allele. Albumin is the major
protein in plasma and interstitial fluids, its levels ranging from
2% to 5%. Tomimic the protein-rich composition of extracellular
fluids, culture medium was therefore supplemented with 10%
dialyzed fetal bovine serum ±3% albumin. When placed in
glucose-free medium, both wild-type and K-RasG12D MEFs
ceased to proliferate, regardless of the presence of 3% albumin
(Figure 1A). When cells were subjected to non-essential amino
acid (NEAA) starvation, albumin supplementation modestly
improved viability. When cells were placed in medium lacking a260 Cell 162, 259–270, July 16, 2015 ª2015 Elsevier Inc.single NEAA, glutamine, albumin supple-
mentation allowed K-RasG12DMEFs to in-
crease in cell numbers, albeit to a minor
extent.
In contrast to the above results, addi-
tion of 3% albumin caused a striking
rescue of cell survival in medium lacking
all essential amino acids (EAAs) (Figures1A and S1A). When starved for a single EAA, leucine, which is
the most abundant amino acid in both albumin and the mamma-
lian proteome, viability of wild-type MEFs was completely
restored by albumin supplementation (Figure 1A). K-RasG12D
MEFs were able to sustain proliferation in leucine-free medium
containing 3% albumin, with cell numbers increasing over
several consecutive days (Figure 1B). Because growing cells
must acquire leucine from exogenous sources to support protein
synthesis, these results suggest that K-RasG12D MEFs could
derive leucine from extracellular proteins. However, we noted
that albumin supplementation of amino-acid-deficient medium
could sustain only limited cell proliferation as compared to
amino-acid-replete medium (Figure 1A).
Besides Ras, PI3-kinase/Akt signaling is a second key
pathway that instructs cells to engage in nutrient uptake (Mann-
ing and Cantley, 2007). However, expressing myristoylated Akt 1
or PTEN short hairpin RNA (shRNA) did not improve the response
of cells to albumin supplementation of leucine-free medium (Fig-
ures 1C and S1B). In contrast, inducing the expression of consti-
tutively active K-RasG12V or H-RasG12V supported proliferation
under these conditions (Figures S1C and S1D), consistent with
what we observed in MEFs harboring an endogenous K-RasG12D
allele. The capacity of constitutively activated Ras signaling to
sustain moderate levels of proliferation in medium that is
protein-rich but amino-acid-deficient is consistent with the
shared ability of Ras GTPases to enhance macropinocytosis.
One mechanism by which oncogenic Ras signaling has been
proposed to sustain cell viability during starvation is increased
autophagy to recover nutrients from catabolism of intracellular
macromolecules (Pylayeva-Gupta et al., 2011). To examine the
role of autophagy in cell growth that utilizes extracellular proteins
Figure 2. Macropinocytosis and Lysosomal Degradation of Extra-
cellular Proteins Supports Growth of Ras Mutant Cells during EAA
Starvation
(A) Growth curve of wild-type and K-RasG12D MEFs in amino-acid-deficient
medium containing EAAs at 5% of the levels in complete medium ±3%
albumin.
(B) Growth curve of K-RasG12D MEFs in amino-acid-deficient medium con-
taining 5% EAAs supplemented with indicated albumin concentrations.
(C) Uptake and intracellular degradation of albumin in K-RasG12D MEFs,
assessed by fluorescently labeled BSA andDQ-BSA. Protease inhibitors: 2 mM
pepstatin A, 2 mM E-64, 10 mM leupeptin. Scale bars, 10 mm.
(D) Growth curve of K-RasG12DMEFs in leucine-free medium ±3%albumin and
protease inhibitors as in (C).
(E) Cell numbers of K-RasG12D MEFs at day 3 of culture in leucine-free
medium ±3% albumin and 25 mM EIPA. The dashed line indicates starting cell
numbers. ***p < 0.001.
Data are represented as mean ± SD (n = 3). See also Figure S2.as a nutrient source, we determined requirements for the auto-
phagy initiator kinases Ulk1/2. Wild-type and Ulk1/2 double-
knockout (DKO) MEFs expressing K-RasG12V or H-RasG12V
alleles could sustain proliferation in leucine-free medium when
3% albumin was added as an exogenous amino acid source
(Figures S1E and S1F). Loss of Ulk1/2 did not impair extracellular
protein-dependent cell growth. Instead, Ulk1/2 DKO MEFs
proliferated at significantly higher rates than wild-type controls.
Thus, not only are the autophagy initiator kinases Ulk1/2
dispensable for the utilization of extracellular proteins as nutri-
ents, but loss of Ulk1/2-dependent autophagy actually improves
the ability of Ras mutant cells to proliferate under these nutri-
tional conditions.
We next asked whether albumin supported cell proliferation in
medium containing reduced amounts of all EAAs. When EAAs
were supplied at 5% of the levels present in complete medium,
wild-type and K-RasG12D MEFs ceased to proliferate and lost
viability over time (Figure 2A). Addition of 3% albumin improved
survival of wild-type MEFs but did not support their proliferation.
In contrast, albumin supplementation caused a significant in-
crease in proliferation of K-RasG12D MEFs. As the proteins
provided in 10% dialyzed serum did not suffice to promote cell
proliferation during EAA starvation, we determined the concen-
tration of albumin required for proliferation under these condi-
tions. Wild-type MEFs cultured in low-EAA medium displayed
improved viability in response to increasing albumin levels
(1%–3%) (Figure S2A). K-RasG12D MEFs could sustain prolifera-
tion when at least 1% albumin was added, and their proliferation
rate increased progressively as the albumin concentration was
raised to 3% (Figure 2B). Thus, albumin must be supplied at
physiological levels to support cell survival and growth in EAA-
deficient medium. This may explain why the protein-poor media
formulations commonly used in cell culture do not suffice for
MEFs to proliferate during EAA starvation.
To characterize how cells derive leucine from extracellular pro-
teins, cellular albumin uptake was investigated using constitu-
tively fluorescent albumin and intracellular albumin proteolysis
using a self-quenched albumin that emits fluorescence upon
degradation (DQ-BSA) (Reis et al., 1998). After 1.5 hr label up-
take, K-RasG12DMEFs displayed multiple intracellular structures
marked by both albumin and DQ-BSA (Figure 2C). Adding lyso-
somal protease inhibitors did not perturb albumin internalization
but caused a strong decrease in DQ-BSA fluorescence. We next
asked whether lysosomal albumin degradation was required to
support growth during leucine starvation. Indeed, lysosomal
protease inhibitors or the lysosomal acidification inhibitor chloro-
quine suppressed proliferation of K-RasG12D MEFs in leucine-
free medium containing 3% albumin (Figures 2D and S2B). Ras
GTPases can promote cellular uptake of macromolecules
through macropinocytosis (Bar-Sagi and Feramisco, 1986).
Consistently, K-RasG12D MEFs displayed higher macropinocytic
activity than wild-type controls (Figure S2C). To investigate
whether this endocytic pathway contributed to albumin-depen-
dent growth, cells were treated with the Na+/H+ exchange
inhibitor EIPA, which blocks macropinocytosis but not other en-
docytic pathways (West et al., 1989). Cell proliferation in leucine-
free medium +3% albumin was strongly decreased by EIPA
treatment, but restored when free leucine was added to cultureCell 162, 259–270, July 16, 2015 ª2015 Elsevier Inc. 261
Figure 3. Lysosomal Degradation of Internalized Proteins Activates the mTORC1 Pathway
(A) Comparison of mTORC1 activation in wild-type and K-RasG12DMEFs, analyzed by western blotting (WB). MEFs were starved of EAAs for 1 hr and then placed
in medium containing EAAs or 3% albumin or in fresh EAA-free medium for 4 hr.
(B) Time course of mTORC1 activation in K-RasG12D MEFs by stimulation with 3% albumin after 1 hr EAA starvation, analyzed by WB.
(C–F) Effects of inhibiting lysosomal function or macropinocytosis on albumin-dependent mTORC1 activation, analyzed byWB. K-RasG12DMEFs were starved of
EAAs for 1 hr and then placed inmedium containing EAAs or 3%albumin or in fresh EAA-freemedium for 3 hr. (C) bafilomycin A1, (D) lysosomal protease inhibitors
(10 mM pepstatin A, 20 mM E-64), (E) EIPA (Na+/H+ exchange inhibitor), or (F) IPA-3 (PAK1 inhibitor) were added at the onset of starvation.
See also Figure S3.medium (Figure 2E). Together, these data show that macropino-
cytic uptake and lysosomal degradation of extracellular proteins
can provide nutritional benefits during EAA starvation.
Catabolism of Extracellular Proteins Induces Lysosomal
Recruitment and Activation of mTORC1
Cells can sense EAAs through the mTORC1 pathway, which in-
tegrates amino acid levels with inputs from growth factor
signaling to promote cell growth (Ma and Blenis, 2009; Shimo-
bayashi and Hall, 2014). When cells are placed in EAA-free
medium, the ability of mTORC1 to phosphorylate downstream
targets is repressed. To test if catabolism of extracellularly pro-
vided proteins could restore mTORC1 activity in the absence
of EAAs, mTORC1 was inactivated by subjecting MEFs to 1 hr
EAA starvation. Fresh medium containing EAAs or different con-
centrations of albumin was then added and mTORC1 re-activa-
tion assessed by western blotting against phosphorylated S6K1.
Supplementing EAA-free medium with 1%–3% albumin caused
a concentration-dependent increase in S6K1 phosphorylation in
both wild-type andK-RasG12DMEFs, whichwas completely sup-
pressed by the mTOR inhibitor torin 1 (Figure S3A). Thus, phys-
iological levels of albumin can activate the mTORC1 pathway.
Although wild-type and K-RasG12D MEFs exhibited comparable
mTORC1 activation in response to EAAs, K-RasG12D MEFs dis-
played higher mTORC1 activity upon addition of 3% albumin
(Figure 3A). Similarly, H-RasG12V expression increased mTORC1262 Cell 162, 259–270, July 16, 2015 ª2015 Elsevier Inc.activity in response to albumin (Figure S3B). Conversely,
elevating PI3-Kinase/Akt signaling through shRNA-mediated
depletion of PTEN increased mTORC1 activation by EAAs but
not albumin (Figure S3C). These data suggest that Ras signaling
enhancesmTORC1 activation in response to albumin stimulation
through the amino-acid-sensing branch rather than the growth
factor-regulated branch of the pathway.
Extracellularly provided EAAs are rapidly taken up by cells
through transmembrane transporters and activate mTORC1
within minutes (Nicklin et al., 2009). To examine the kinetics of
mTORC1 pathway activation by extracellular proteins, mTORC1
re-activation in response to albumin stimulation was followed
over time. Re-addition of EAAs caused rapid phosphorylation
of mTORC1 targets such as S6K1, Grb10, and Ulk1 as well as
the S6K target ribosomal protein S6 (Figures 3B and S3D)
(Kang et al., 2013; Nicklin et al., 2009). In contrast, in response
to albumin, mTORC1-dependent phosphorylation of these pro-
teins resumed only after 2 hr and reached maximal levels after
4 hr. Thus, extracellular proteins activate the mTORC1 pathway
more slowly than EAAs, suggesting that distinct cellular pro-
cesses are involved in mTORC1 activation by these nutrients.
We next asked whether macropinocytosis and lysosomal pro-
teolysis were required for mTORC1 activation by extracellular
proteins. The lysosomal acidification inhibitors bafilomycin
A1 and chloroquine did not perturb mTORC1 activation by
EAAs (Figures 3C and S3E). In contrast, even low concentrations
of either inhibitor strongly suppressed albumin-dependent
mTORC1 activation. Similarly, protease inhibitors blocked
mTORC1 activation in response to stimulation with albumin (Fig-
ure 3D). To establish the relevance of macropinocytosis, the
effects of pharmacological inhibitors of macropinocytosis in-
cluding the Na+/H+ exchange inhibitor EIPA, the Pak1 inhibitor
IPA-3 and the actin inhibitors jasplakinolide and cytochalasin
D (Mercer and Helenius, 2009) were investigated. All these
inhibitors strongly reduced mTORC1 activation by addition of
albumin but not by re-addition of EAAs (Figures 3E, 3F, S3F,
and S3G).
Amino acids signal to mTORC1 by inducing its translocation to
lysosomal membranes, where it can be activated by further in-
puts from growth factor signaling (Sancak et al., 2010). To deter-
mine whether extracellular proteins similarly regulated mTORC1
by inducing its recruitment to lysosomes, K-RasG12D MEFs were
subjected to 1 hr EAA starvation and re-fed with EAAs or 3%
albumin, and the subcellular localization of mTOR kinase was
monitored by immunofluorescence. mTOR was distributed
throughout the cytoplasm in EAA-starved cells. Upon albumin
addition, mTOR localized to punctate structures that were
marked by the lysosomal membrane protein LAMP2, similar to
the pattern observed upon re-addition of free EAAs (Figure 4A).
Inhibiting lysosomal proteolysis with bafilomycin A1 completely
blocked movement of mTOR to lysosomal membranes in
response to albumin but not to EAAs (Figure 4B).
EAAs inducemovement of mTORC1 to lysosomal membranes
through a mechanism that requires the lysosome-associated
Rag GTPases (Kim et al., 2008; Sancak et al., 2008). In contrast,
glutamine can activate mTORC1 in a Rag-independent mecha-
nism (Jewell et al., 2015). To investigate whether mTORC1
activation by lysosomal proteolysis of albumin depended on
Rag GTPases, the consequences of shRNA-mediated knock-
down of RagA and RagB was determined. Depletion of
RagA/B resulted in diffuse localization of mTOR throughout the
cytosol, regardless whether medium contained albumin or
EAAs (Figure 4C). Consistently, neither albumin nor EAAs
could induce mTORC1-dependent phosphorylation of S6K1 in
RagA/B knockdown cells (Figure S4). Thus, both extracellular
proteins and EAAs activate mTORC1 through a Rag-dependent
mechanism.
mTORC1 Suppresses Cell Growth that Relies on
Extracellular Proteins as Nutrients
To examine the signaling pathways downstream of Ras that
contribute to a cell’s ability to utilize extracellular proteins as
an amino acid source, we determined the effects of inhibitors
against MEK1/2, PI3-kinase, tyrosine kinases, and mTOR on
proliferation of K-RasG12D MEFs in leucine-free medium +3%
albumin. To our surprise, mTOR inhibition did not retard cell pro-
liferation in leucine-free medium supplemented with albumin.
Rather, each of themTOR inhibitors, includingmTOR/PI3-kinase
dual inhibitors, enhanced proliferation under these conditions
(Figure 5A, left panel; Figure S5A), although they effectively
blocked mTOR signaling activity (Figure 5B). In contrast, inhibi-
tion of MAP kinase, PI3-kinase, or tyrosine kinase signaling
modestly decreased cell proliferation in leucine-free medium
(Figure 5A, left panel). The effects of these kinase inhibitorswere different in leucine-containing medium, where mTOR inhi-
bition was particularly effective at suppressing cell proliferation
(Figure 5A, right panel). We next examined concentration-
dependent effects of mTOR inhibitors on cell growth. Raising
concentrations of torin 1 from 50 to 300 nM progressively
improved cell proliferation in leucine-free medium +3% albumin,
suggesting that proliferation is inversely correlated with mTOR
signaling activity when cells use albumin as a source of leucine
(Figure 5C). In contrast, cell proliferation was significantly higher
when free leucine was provided extracellularly but decreased
with increasing doses of torin 1 (Figure S5B). Similarly, torin 1
treatment induced several carcinoma cell lines harboring acti-
vating Ras mutations to proliferate in leucine-free medium +3%
albumin, while it strongly decreased their proliferation in leucine-
containing medium (Figure S5C). As albumin provides a mixture
of all proteinogenic amino acids, we also examined whether it
could support survival/growth of cells in medium lacking other
single EAAs (isoleucine, lysine, or arginine). Indeed, physiolog-
ical levels of albumin rescued cell viability, and inhibition of
mTOR signaling by torin 1 induced cells to robustly proliferate
in medium lacking these EAAs (Figure S5D).
mTOR kinase is present in two distinct complexes: mTORC1,
which regulates growth in response to nutrients and growth
factor signaling, and mTORC2, which is a component of the
PI3-kinase signaling pathway (Shimobayashi and Hall, 2014).
To dissect their role in regulating albumin-dependent growth,
the essential mTORC1 component, Raptor, or the essential
mTORC2 component, Rictor, was depleted in K-RasG12D MEFs
through shRNA-mediated knockdown (Figure S5E). Rictor
knockdown did not enhance cell proliferation during leucine
deprivation, regardless of the presence of 3% albumin (Figures
5D and 5E). In contrast, Raptor knockdown caused a dramatic
increase in proliferation of K-RasG12D MEFs in leucine-free me-
dium supplemented with albumin, with cells undergoing almost
one population doubling per day. Thus, mTORC1 is a negative
regulator of cell growth that relies on extracellular proteins as
an amino acid source.
mTORC1 Inhibition Enhances Lysosomal Degradation of
Internalized Albumin
We reasoned that the recovery of leucine from extracellular
proteins constituted the rate-limiting step for cell growth in
leucine-free medium. This suggested that mTORC1 suppresses
extracellular protein-dependent growth by restricting a cell’s
access to the amino acid content of extracellular proteins,
conceivably by blocking either their endocytosis or lysosomal
degradation. To distinguish these possibilities, we first tested
whethermTORC1 inhibition increased internalization of extracel-
lular macromolecules. However, neither torin 1 nor Raptor
knockdown elevated cellular uptake of fluorescently labeled
dextran or albumin, indicating that mTORC1 signaling does not
inhibit bulk internalization of extracellular macromolecules (Fig-
ures S6A–S6C).
We next examined whether mTORC1 inhibition affected lyso-
somal degradation of internalized proteins. K-RasG12D MEFs
were placed in medium containing DQ-BSA and, to mark lyso-
somes, lysotracker ± torin 1, and the fluorescent signal gener-
ated by lysosomal proteolysis of DQ-BSA was followed overCell 162, 259–270, July 16, 2015 ª2015 Elsevier Inc. 263
(legend on next page)
264 Cell 162, 259–270, July 16, 2015 ª2015 Elsevier Inc.
Figure 5. mTORC1 Signaling Is a Negative
Regulator of Extracellular Protein-Depen-
dent Growth
(A) Cell numbers of K-RasG12D MEFs at day 3
of culture in leucine-containing or leucine-free
medium +3% albumin and following inhibitors:
MEK1/2 (1 mM PD0325901, 50 mM PD98059), PI3-
kinase (25 mM LY294002, 2 mM wortmannin),
tyrosine kinases (50 mM genistein), mTOR (50 nM
rapamycin, 250 nM torin 1), and mTOR/PI3-kinase
(0.5 mM BEZ235, 0.5 mM GDC0980). Dashed lines
indicate starting cell numbers.
(B) mTOR, PI3-kinase, and MAP kinase pathway
activity in K-RasG12D MEFs cultured for 1 day in
leucine-free medium +3% albumin, analyzed by
WB. Inhibitors were as in (A).
(C) Growth curve of K-RasG12D MEFs in leucine-
free medium ±3% albumin and indicated con-
centrations of torin 1.
(D) Growth curve of K-RasG12D MEFs expressing
shRNA against Raptor, Rictor, or control in
leucine-free medium ±3% albumin.
(E) Bright-field images of K-RasG12D MEFs ex-
pressing shRNA against Raptor, Rictor, or control
at day 4 of culture in leucine-free medium ±3%
albumin. Scale bars, 50 mm.
Data are represented as mean ± SD (n = 3). See
also Figure S5.time. mTOR inhibition caused a dramatic increase in the fluores-
cence dequenching of DQ-BSA, indicative of its enhanced
degradation (Figures 6A and 6B). Similarly, inhibiting mTORC1
by Raptor knockdown increased cellular DQ-BSA fluorescence
(Figure S6D). Blocking lysosomal proteolysis with chloroquine
or lysosomal protease inhibitors abrogated DQ-BSA degrada-
tion in torin-1-treated cells (Figure S6E). Thus, mTORC1 nega-
tively regulates lysosomal degradation of proteins that were
taken up from the environment.Figure 4. Lysosomal Degradation of Internalized Proteins Induces Lysosomal Recruitment of
(A) Lysosomal recruitment of mTOR by extracellular proteins or EAAs, analyzed by immunofluorescence a
K-RasG12D MEFs were starved of EAAs for 1 hr and then placed in medium containing EAAs or 3% albumin
(B) Consequences of inhibiting lysosomal proteolysis on lysosomal recruitment of mTOR by extracellular pro
in (A). 200 nM bafilomycin A1 was added at the onset of EAA starvation.
(C) Consequences of RagA/B knockdown on lysosomal recruitment of mTOR in K-RasG12D MEFs treated an
Scale bars, 10 mm. See also Figure S4.
Cell 162, 259–To further investigate how Ras and
mTORC1 signaling regulated lysosomal
proteolysis of internalized proteins, we
compared the effects of mTORC1 inhibi-
tion and K-Ras activation. Inhibiting
mTORC1 with torin 1 in wild-type MEFs
caused a significant increase in DQ-BSA
fluorescence (Figures 6C and 6D). Simi-
larly, MEFs harboring the constitutively
active K-RasG12D mutation displayed
higher DQ-BSA degradation than wild-
type MEFs. Combining torin 1 treatment
with constitutive K-Ras activation had
synergistic effects and increased DQ-BSA proteolysis almost four times more than either manipulation
alone. Thus, K-Ras enhances a cell’s ability to take up and
degrade extracellular proteins, whereas mTORC1 specifically
restricts their lysosomal degradation.
One mechanism by which mTORC1 signaling might impede
degradation of internalized proteins is to suppress expression
of genes involved in endocytosis or lysosomal biogenesis (Shi-
mobayashi and Hall, 2014). To address whether mTORC1 inhibi-
tion enhanced DQ-BSA degradation through secondary effectsmTOR
gainst mTOR and the lysosomal marker LAMP2.
, or in fresh EAA-free medium for 2 hr.
teins in K-RasG12D MEFs treated and analyzed as
d analyzed as in (A).
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Figure 6. mTORC1 Suppresses Lysosomal Degradation of Internalized Proteins
(A) Time-course of lysosomal DQ-BSA degradation in K-RasG12D MEFs in the presence or absence of 250 nM torin 1.
(B) Quantification of DQ-BSA fluorescence of cells shown in (A).
(C) Lysosomal degradation of DQ-BSA in wild-type and K-RasG12D MEFs after 6 hr DQ-BSA uptake in the presence or absence of 250 nM torin 1.
(D) Quantification of DQ-BSA fluorescence of cells shown in (C).
Data are represented as mean ± SD (nR 5 fields of view with >20 cells each). *p < 0.05, ***p < 0.001. Scale bars, 20 mm. See also Figure S6.of transcriptional changes, we determined the time frame during
which mTORC 1 inhibitors exerted their effect. Pre-treating
K-RasG12D MEFs with torin 1 for 6 or 16 hr did not increase the
rate of DQ-BSA degradation (Figure S6F). Moreover, when
transcription was blocked by actinomycin D or triptolide, the
torin-1-induced increase in DQ-BSA fluorescence was unaf-
fected (Figure S6G). Thus, lysosomal proteolysis of internalized
proteins is an immediate cellular response tomTORC1 inhibition.
Autophagic engulfment and degradation of intracellular constit-
uents is suppressed by mTORC1 under nutrient-replete condi-
tions by inhibition of the autophagy initiator kinases Ulk1/2 (He
and Klionsky, 2009; Mizushima, 2010). As endocytosis and auto-
phagy are both vesicular trafficking pathways that deliver macro-
molecules to the lysosome, we examined the consequences of
Ulk1/2 deletion on DQ-BSA proteolysis. Ulk1/2 wild-type and266 Cell 162, 259–270, July 16, 2015 ª2015 Elsevier Inc.DKO MEFs expressing K-RasG12V degraded DQ-BSA at similar
rates and responded to torin 1 treatment with comparable in-
crease in DQ-BSA proteolysis (Figure S6H). Moreover, torin 1
enhanced proliferation of Ulk1/2 DKO MEFs in leucine-free
medium containing 3% albumin (Figure S6I). Thus, mTORC1
suppresses lysosomal proteolysis of extracellular proteins by a
mechanism that is distinct from its regulation of autophagy.
mTORC1 Signaling Can Have Opposite Effects on Cell
Proliferation Depending on a Cell’s Source of Amino
Acids
While it has been shown in many different systems that mTORC1
promotes growth when amino acids are abundant extracellu-
larly, the above data indicated that mTORC1 could suppress
cell growth that relies on the catabolism of extracellular proteins.
Figure 7. mTORC1 Signaling Has Opposing
Effects on Cell Proliferation in Nutrient-Rich
and Nutrient-Depleted Conditions
(A and B) Cell numbers of K-RasG12D MEFs
(A) ±250 nM torin 1, (B) expressing Raptor or
control shRNA, at day 3 of culture in medium
containing 3% albumin and indicated amounts
of EAAs.
(C) Proliferation of pancreatic tumor cells in control
and rapamycin-treated KPC mice, analyzed by
immunohistochemistry against Ki-67. Scale bars,
400 mm; scale bars in blow-ups, 50 mm.
(D) Quantification of Ki-67-positive tumor cells in
outer and inner tumor regions as shown in (C).
(E) Volume increase of pancreatic tumors in con-
trol and rapamycin-treated KPC mice, quantified
by 3D high-resolution ultrasound.
(F) Growth curve of Raptor KO MEFs in leucine-
containing or free medium +3% albumin.
(G) Cell numbers of wild-type MEFs expressing
Raptor or control shRNA at day 3 of culture in
medium containing 3% albumin and indicated
amounts of EAAs.
Data in (A), (B), (F), and (G) are represented as
mean ± SD (n = 3). Dashed lines indicate starting
cell number. Data in (D) and (E) are represented as
mean ± SEM (n = 5). *p < 0.05, **p < 0.01, ***p <
0.001. See also Figure S7.This led us to investigate the impact of mTORC1 inhibition on
growth of K-RasG12D MEFs in medium containing decreasing
amounts of EAAs, but supplemented with 3% albumin as an
alternative EAA source. Torin 1 treatment or Raptor knockdown
strongly decreased cell proliferation when EAAs were abundant
extracellularly (Figures 7A and 7B). However, whereas the prolif-
eration of control cells quickly dropped with decreasing EAA
levels, cells treated with torin 1 or expressing Raptor shRNA dis-
played only slightly reduced proliferation over a 10-fold range of
EAA concentrations. At low EAA concentrations, torin 1 treat-
ment or Raptor knockdown significantly improved cell prolifera-
tion. These results suggest that mTORC1 signaling stimulatesCell 162, 259–proliferation of K-RasG12D MEFs in
amino-acid-rich medium but restricts it
under conditions when extracellular pro-
teins become a required source of essen-
tial amino acids.
Rapamycin Enhances theGrowth of
K-Ras-Induced Pancreatic Tumors
In Vivo
To ask whether mTORC1 inhibition could
promote proliferation of K-Ras mutant
cells in vivo, we examined the effects of
mTORC1 inhibition on the development
of pancreatic ductal adenocarcinoma
(PDA), using a genetically engineered
mouse model that expresses endoge-
nous alleles of mutant K-Ras and p53
specifically in the pancreas (KPC) (Hin-
gorani et al., 2005). In humans, K-Ras ismutated in the majority of pancreatic cancers; consistently,
tumor cells of KPC mice were recently shown to internalize
high-molecular-weight dextran through macropinocytosis, indi-
cating that they have the potential to access extracellular
proteins (Commisso et al., 2013). Moreover, the tumor microen-
vironment of pancreatic cancer is poorly vascularized and highly
nutrient depleted (Kamphorst et al., 2015), which raises the pos-
sibility that extracellular proteins could function as an important
alternative nutrient source in this context.
KPC mice with established tumors of comparable size were
treated over the course of 8 days with rapamycin, and cell prolif-
eration was examined by Ki-67 staining of tumor tissue. Because270, July 16, 2015 ª2015 Elsevier Inc. 267
mTORC1 inhibition enhanced cell growth in cultured cells specif-
ically during amino acid starvation, we examined the effects of
rapamycin on proliferation of tumor cells in interior, hypovascu-
larized tumor regions that were negative for the endothelial
marker CD31. Indeed, rapamycin treatment caused a striking
increase in the number of Ki-67-positive cells in those tumor re-
gions despite the absence of the mTORC1 downstream target,
phosphorylated S6 (Figures 7C, 7D, and S7A). In contrast, rapa-
mycin decreased the fraction of Ki-67-positive cells in outer,
vascularized tumor regions with a concomitant decrease in
phospho-S6. These data indicate that pancreatic cancer cells
respond to rapamycin in vivo depending on the tumor microen-
vironment they reside in; while rapamycin decreases cell prolifer-
ation in outer, vascularized regions, it enhances proliferation in
interior, hypovascularized regions. These findings support the
idea that mTORC1 can function as a suppressor of cell growth
during nutrient starvation. Strikingly, rapamycin treatment signif-
icantly accelerated tumor growth in KPC mice (Figure 7E).
Genetic Ablation of mTORC1 Signaling Can Induce
Extracellular Protein-Dependent Growth Independently
of Ras Transformation
Finally, to determine if the role of mTORC1 in suppressing utiliza-
tion of extracellular proteins as an amino acid source to support
cell growth was restricted to Ras-transformed cells, we investi-
gated the consequences of mTORC1 inhibition in cells harboring
wild-type Ras alleles. Wild-type MEFs expressing Raptor shRNA
or treated with mTOR inhibitors could robustly proliferate in
leucine-free medium supplemented with 3% albumin (Figures
S7B–S7D). To more stringently block mTOR signaling, Raptor
or Rictor were genetically ablated from MEFs harboring condi-
tional alleles (Figure S7E) (Cybulski et al., 2012). While Raptor
knockout cells displayed strongly decreased cell proliferation
in nutrient-replete medium as compared to wild-type controls,
they could sustain proliferation in leucine-free medium +3%
albumin (Figure 7F). In contrast, deletion of Rictor only modestly
decreased cell proliferation in leucine-containing medium and
did not result in growth of leucine-deprived cells in albumin-sup-
plemented medium (Figure S7F). The proliferation of wild-type
MEFs expressing control or Raptor shRNA was also examined
in medium containing decreasing amounts of EAAs as well as
3% albumin as an alternative EAA source. Raptor knockdown
impaired cell proliferation under EAA-replete conditions (Fig-
ure 7G). However, the difference in cell proliferation between
control and Raptor knockdown cells diminishedwhen EAA levels
were reduced, and, at low EAA levels, Raptor knockdown
enhanced proliferation.
DISCUSSION
mTORC1 Suppresses the Utilization of Extracellular
Proteins as Nutrients
The above results demonstrate that in mammalian cells
mTORC1 signaling suppresses lysosomal catabolism of proteins
that were taken up from the environment. As a corollary,
mTORC1 inhibition enhances cell proliferation that relies on
extracellular proteins as nutrients, for instance, in cultured cells
deprived of EAAs or pancreatic cancer cells residing in poorly268 Cell 162, 259–270, July 16, 2015 ª2015 Elsevier Inc.vascularized tumor regions. It is well known that the mTORC1
pathway is a potent stimulator of cell growth under nutrient-
rich conditions, in part through enhancing translation (Ma and
Blenis, 2009; Shimobayashi and Hall, 2014). However, the ability
of mTORC1 to promote net protein synthesis strictly requires an
exogenous source of amino acids. The present work indicates
that by restricting amino acid recovery from extracellular pro-
teins, mTORC1 couples cell growth to extracellular availability
of free amino acids. This suggests that mTORC1 inhibition can
promote growth under conditions when protein biosynthesis is
limited by the acquisition of amino acids rather than the effi-
ciency of translation. Whether mTORC1 stimulates or sup-
presses cell growth may therefore depend on a cell’s amino
acid source.
Previous work showed that inhibition of mTORC1 could sup-
port cell survival in the absence of a source of extracellular
EAAs.When cells are deprived of leucine in the absence of extra-
cellular proteins, the ensuing inactivation of mTORC1 leads to
de-repression of the autophagy initiation kinases Ulk1/2, which
trigger the formation of autophagosomes to engulf intracellular
constituents for subsequent delivery to the lysosome (He and
Klionsky, 2009; Mizushima, 2010). Through this mechanism,
autophagy supports cell survival during leucine deprivation.
However, catabolism of intracellular proteins cannot lead to
net acquisition of leucine (or other EAAs) required for cell growth
and proliferation. Rather, autophagic degradation of intracellular
proteins recovers sufficient EAAs for cells to engage in adaptive
protein synthesis to sustain cell survival during limited periods of
nutrient deprivation. The work presented here demonstrates that
mammalian cells can utilize extracellular proteins as a source of
EAAs that allows sustained cell viability. If cells catabolize suffi-
cient amounts of extracellular proteins, as a result of activating
mutations in Ras and/or suppression of mTORC1, they can
even support net protein synthesis to increase in biomass and
proliferate. The above data further show that Ulk1/2 are dispens-
able for extracellular protein-dependent growth of Ras mutant
cells. In fact, genetic deletion of Ulk1/2 enhances cell prolifera-
tion uponmTORC1 inhibition. This suggests that the degradation
of intracellular constituents through autophagy as a result of
mTORC1 inhibition can limit the rate at which amino-acid-
deprived cells can grow by taking up and degrading extracellular
proteins.
Amino acids regulate mTORC1 activity by inducing its recruit-
ment to lysosomal membranes (Sancak et al., 2010). The present
work demonstrates that lysosomal degradation of endocytosed
proteins regulates the mTORC1 pathway at the same step as
amino acids that were imported from the environment in their
monomeric form: both nutrients induce Rag-dependent recruit-
ment of mTORC1 to lysosomal membranes, which permits its
subsequent activation by growth factor signaling. Similarly, lyso-
somal catabolism of intracellular proteins that were delivered
through autophagy leads to recruitment of mTORC1 to this
organelle (Yu et al., 2010). Together, these data suggest that
the regulation of mTORC1 activity at the lysosome constitutes
a sensitive mechanism that allows cells to monitor amino acids
recovered from proteins that were delivered through endocy-
tosis or autophagy. Conversely, being activated at lysosomal
membranes, mTORC1 may be well positioned to function as a
regulator of cargo delivery to the lysosome by these membrane
trafficking pathways. Notably, proteins that regulate endosomal
trafficking have been recently emerging as a novel class of
mTORC1 substrates (Hsu et al., 2011; Kim et al., 2015; Yu
et al., 2011).
Implications for the Use of mTOR Inhibitors as
Therapeutics
The present results may also shed light on the puzzling lack of
efficacy of mTOR inhibitors as cancer therapeutics. There has
been much effort over the last several years to target the
mTORC1 pathway in cancer treatment. These studies have
been motivated by the observation that human tumors often
display elevated mTORC1 activity, commonly because of muta-
tions in its upstream activator, the PI3-kinase pathway (Manning
and Cantley, 2007). However, recent clinical trials showed only
limited efficacy of rapamycin analogs (rapalogs) in a variety of
solid tumors. The present work reveals an intrinsic weakness
of mTOR inhibitors in cancer treatment. By enhancing catabo-
lism of extracellularly derived proteins, mTOR inhibitors increase
the use of extracellular proteins as alternative nutrients to sup-
port survival and sustain growth. This may be particularly impor-
tant in nutrient-depleted tumor microenvironments or during
metastasis, when tumor cells must adapt to novel metabolic
niches. These findings predict that the growth promoting effects
of mTOR inhibitors correlate with the capacity of cancer cells to
take up sufficient extracellular proteins through endocytic path-
ways such as Ras-directed macropinocytosis. Consistently,
treating KPC mice with rapamycin increases proliferation of
pancreatic cancer cells that reside in poorly vascularized tumor
regions and accelerates net tumor growth. This may explain
the failure of mTOR inhibitors in the treatment of a variety of tu-
mor types with activating mutations in Ras signaling, such as
pancreatic cancer, in which K-Ras is the major driver oncogene,
(Javle et al., 2010) or neurofibromatosis, which is caused by
mutation in the Ras suppressor NF1.
One current explanation for the limited success of rapalogs is
that they alleviate feedback repression of PI3-kinase/Akt sig-
naling. This led to thedevelopment of active sitemTOR inhibitors,
which by targeting mTOR kinase inhibit mTORC1 and the Akt
activator mTORC2, as well as dual mTOR/PI3-kinase inhibitors.
The efficacy of these inhibitors in cancer therapy is currently be-
ing investigated, but the above data show that in cultured cells,
the different classes of mTOR inhibitors share the caveat of pro-
moting nutritional utilization of extracellular proteins. However,
our work suggests that an alternative approach of combining
mTOR inhibitors with inhibitors that block uptake or lysosomal
degradation of extracellular proteins could achieve greater effi-
cacy. When evaluating the role of mTORC1 signaling in tumori-
genesis, it may also be worth considering insights from cancer
genome sequencing efforts. Relatively few cancers were found
to harbor mutations in mTOR kinase or direct pathway regulators
that cause constitutive pathway activation. In contrast,mutations
in the upstream PI3-kinase/Akt pathway are prevalent in human
cancers (Manning and Cantley, 2007). This conceivably allows
cancer cells to increase mTORC1 activity under nutrient-rich
conditions, while not abrogating its regulation by amino acids,
thus allowing tumor cells to adapt to nutrient deprivation.Macropinocytosis of Extracellular Macromolecules as a
Strategy of Nutrient Acquisition in Eukaryotic Cells
The present work demonstrates that mammalian cells can tap
extracellular proteins as a source of EAAs to sustain survival
and proliferation. These data support and extend recent work
showing that Ras-directed protein macropinocytosis could
alleviate the dependence of transformed cells on extracellular
glutamine supply (Commisso et al., 2013). Ras-induced macro-
pinocytosis of extracellular proteins has been previously recog-
nized to sustain growth of unicellular amoeboid eukaryotes such
as Dictyostelium discoideum (Amyere et al., 2002). Taken
together, these findings indicate that macropinocytosis consti-
tutes an evolutionarily ancient strategy of nutrient acquisition in
eukaryotic cells. Interestingly, macropinocytosis in metazoan
cells is under control of growth factor signaling, and macropino-
cytosis induction is an immediate response of various mamma-
lian cell types to serum stimulation (Amyere et al., 2002; Mercer
and Helenius, 2009). This suggests that growth factors can
instruct cells to take up not only low-molecular-weight nutrients
such as glucose and amino acids, but also extracellular macro-
molecules. However, concerted inputs from growth factor
signaling and amino acids result in mTORC1 activation, which
limits catabolism of proteins internalized from the environment.
Therefore, mTORC1 initiates anabolic cellular metabolism that
utilizes free amino acids, while preventing degradation of extra-
cellularly derived proteins. This mechanism conceivably pre-
vents futile turnover of the proteins contained in body fluids, as
long as monomeric amino acids are available.
EXPERIMENTAL PROCEDURES
For detailed protocols, see Supplemental Experimental Procedures.
Cell Culture and Nutrient Starvation Experiments
Cell culture experiments were performed at 37C and 5% CO2 in DMEM/F12
with 10% dialyzed FBS (molecular weight cutoff 10,000; Gemini Biosystems),
100 U/ml penicillin, 100 mg/ml streptomycin, 5 mM glucose, and 2 mM
glutamine.
For proliferation assays, MEFs were plated in complete medium, 5 hr later
briefly rinsed, and then cultured in starvation medium as indicated. For
EAA titration experiments, EAAs were supplemented at indicated percentages
of 1 3 MEM amino acid solution (M5550, Sigma). Cancer cell lines were
cultured in completemedium for 1 day prior to starvation. Numbers of adherent
cells, which are >95% viable as assessed by trypan blue exclusion (data not
shown), were determined using a Multisizer 4 Coulter Counter (Beckman).
For mTOR activation and localization experiments, cells were rinsed and
then incubated in EAA starvation medium (DMEM/F12 lacking all amino acids
except glutamine) for 1 hr and subsequently placed in medium supplemented
with EAAs (1 3 MEM amino acid solution), albumin (3%, if not stated other-
wise), or fresh EAA-free starvation medium for indicated periods of time.
Mouse Strains and Rapamycin Treatment
The KPC mouse model (LSL-K-RasG12D/+; LSL-Trp53R172H/+; Pdx-1-Cre) has
been described previously (Hingorani et al., 2005). KPC mice develop
advanced and metastatic PDA with 100% penetrance, recapitulating the his-
topathological and clinical features of human PDA. Mice were housed at a
12-hr-light/12-hr-dark cycle. All procedures were conducted in accordance
with the Institutional Animal Care and Use Committee at CSHL.
KPC mice with established tumors of comparable size (7–9 mm in diameter,
n = 5) as determined by ultrasound (Vevo software, Visualsonics) were treated
daily for 8 days by oral gavage with either 5 mg/kg Rapamune (Pfizer) or saline
(vehicle control). The last Rapamune administration was given 4 hr prior to theCell 162, 259–270, July 16, 2015 ª2015 Elsevier Inc. 269
endpoint. Tumor volumesweremeasured from 3D ultrasound images taken on
day 4 and 7 of treatment.
Statistical Analysis
p values were calculated using a two-tailed unpaired t test for proliferation and
fluorescence microscopy experiments of cultured cells and using the Mann-
Whitney nonparametric t test for analysis of murine tumors.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and seven figures and can be found with this article online at http://dx.doi.
org/10.1016/j.cell.2015.06.017.
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